The aggregate exposure assessment is based solely on residential use patterns. Due to the seasonal nature of insect repellents, only short-term exposure scenarios were considered. The incidental oral endpoint for children was based on maternal neurotoxicity in the rat developmental study (NOAEL = 15 mg/kg/day). This endpoint was selected because of the appropriate time period in which the maternal neurotoxic effects were seen. The short-term dermal endpoint for adults and children (15 mg/kg/day) was selected from the same developmental rat study based on neurtoxic effects because no systemic toxicity was present in the 90-day dermal study. A dermal penetration study in rats was submitted for metofluthrin, which suggests a 17% dermal absorption rate. This 17% dermal absorption rate was applied to all dermal exposure scenarios. The 28-day inhalation study in rats provided a sensitive inhalation endpoint (0.099 mg/L) based on mortality and neurotoxic effects (including tremors, hypersensitivity, ataxic gait, tip-toe gait, clonic convulsion, and hypothermia. The default absorption value of 100% was applied to the inhalation exposure assessment. All levels of concern are set at 100, based on a 10x interspecies extrapolation safety factor and 10x intraspecies variability safety factor. The FQPA safety factor was reduced to 1x.